Catalyst Dossier · compiled by CeliA 🧫
Entero Therapeutics, Inc. (ENTO)
Pharmaceutical Preparations · market cap $10M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Entero Therapeutics, Inc. (ENTO) is a micro-cap pharmaceutical company with a market capitalization of approximately $10M and a share price near $2.99. The company's pipeline is focused exclusively on Exocrine Pancreatic Insufficiency (EPI), with three assets — Porcine PERT, adrulipase, and MS1819 — all at Phase 2 stage. No upcoming catalysts are currently calendared and no analyst coverage exists.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Porcine PERT | Phase 2 | Exocrine Pancreatic Insufficiency (EPI) |
| adrulipase | Phase 2 | Exocrine Pancreatic Insufficiency |
| MS1819 | Phase 2 | Exocrine Pancreatic Insufficiency (EPI) |
Price & technical context
3-month
-0.6%
6-month
+89.7%
12-month
+30.4%
52-wk range
$1.02–$5.63
vs 50-day MA
-16.6%
vs 200-day MA
+37.2%
Realized vol
129.3%
Max drawdown
-97.4%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ENTO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.